Dieter Bruno, MD
Neurology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Office
- 1
- Since medical school
- 31 years
- Graduated 1995
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Sequoia Hospital. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bruno’s office at (650) 696-5400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A96007 · Current
Licensed to practise in California · since 2006 · expires 2027-09-30 · Duke University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$99,600
Medicare paid this office $99,600 for 290 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 199 | $25,828 | $85 |
| Return visit (30+ min) | 115 | $17,903 | $118 |
| New patient visit (45+ min) | 46 | $6,830 | $148 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $6,576 | $244 |
| Ultrasound measurement of bladder capacity after voiding | 171 | $3,097 | $12 |
See all 14 services
| Short return visit (20+ min) | 199 | $25,828 | $85 |
| Return visit (30+ min) | 115 | $17,903 | $118 |
| New patient visit (45+ min) | 46 | $6,830 | $148 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $6,576 | $244 |
| Ultrasound measurement of bladder capacity after voiding | 171 | $3,097 | $12 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,881 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,874 | $110 |
| New patient visit (30+ min) | 15 | $1,354 | $90 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $1,246 | $45 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,074 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,040 | $74 |
| Urinalysis, manual test | 123 | $546 | $3 |
| Automated urinalysis test | 80 | $194 | $2 |
| Injection of drug or substance under skin or into muscle | 12 | $180 | $15 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Procedures year by year
| Procedure | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 660 | 476 | 107 | 161 | 256 | 260 |
| Diagnostic exam of bladder and urethra using an endoscope | 155 | 162 | 11 | 30 | 30 | 27 |
| Simple insertion of temporary bladder tube | 123 | 139 | – | – | 50 | – |
| Electronic assessment of bladder emptying | 78 | 47 | – | – | – | – |
| Simple bladder irrigation and/or instillation | 34 | 37 | – | 18 | 23 | – |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 39 | 37 | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
290 Original Medicare patients in 2024. Average age 77 · Women 26% · Also on Medicaid 8% · Health risk score 1.22. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 32% · Coronary heart disease 31% · Chronic kidney disease 27% · Cancer 26% · Atrial fibrillation 22% · Heart failure 19% · Depression 16% · COPD 11% · Stroke 7% · Dementia 6%.
The office billed $422,018, Medicare allowed $131,791 and paid $99,600; for 1,476 services of 61 kinds; $752 of it was for drugs given in the office and $98,848 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 290 | 1,476 | 77 | 1.22 | $422,018 | $99,600 |
| 2023 | 275 | 1,659 | 78 | 1.31 | $452,393 | $104,010 |
| 2022 | 225 | 1,312 | 78 | 1.16 | $334,619 | $80,740 |
| 2021 | 120 | 846 | 78 | 1.04 | $179,753 | $44,864 |
| 2019 | 734 | 5,684 | 77 | 1.21 | $991,035 | $354,690 |
| 2018 | 742 | 5,017 | 76 | 1.19 | $1,133,963 | $404,247 |
| 2017 | 729 | 5,036 | 76 | 1.18 | $1,025,927 | $352,505 |
| 2016 | 723 | 5,068 | 77 | 1.24 | $1,022,284 | $366,548 |
| 2015 | 730 | 4,930 | 76 | 1.27 | $967,853 | $373,947 |
| 2014 | 738 | 5,283 | 77 | 1.24 | $1,063,655 | $387,199 |
| 2013 | 715 | 4,769 | 77 | 1.32 | $985,295 | $374,178 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Short return visit (20+ min) | 185 | $28,231 | $82 |
| Return visit (30+ min) | 99 | $16,411 | $118 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $7,573 | $252 |
| New patient visit (45+ min) | 43 | $6,037 | $140 |
| New patient visit (30+ min) | 40 | $4,081 | $102 |
| Simple insertion of temporary bladder tube | 15 | $3,037 | $61 |
| Ultrasound measurement of bladder capacity after voiding | 145 | $2,839 | $11 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,354 | $118 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $2,010 | $74 |
| Simple bladder irrigation and/or instillation | 16 | $1,803 | $78 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 23 | $1,779 | $44 |
| Urinalysis, manual test | 139 | $665 | $3 |
2022: 11 services
| Return visit (30+ min) | 101 | $16,199 | $113 |
| Short return visit (20+ min) | 128 | $15,347 | $79 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $7,399 | $247 |
| New patient visit (45+ min) | 45 | $5,591 | $124 |
| New patient visit (30+ min) | 33 | $3,254 | $99 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,658 | $87 |
| Ultrasound measurement of bladder capacity after voiding | 107 | $1,638 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,630 | $63 |
| Simple bladder irrigation and/or instillation | 13 | $1,376 | $76 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $1,319 | $34 |
| Urinalysis, manual test | 101 | $474 | $3 |
2021: 7 services
| Return visit (30+ min) | 48 | $8,944 | $124 |
| Short return visit (20+ min) | 50 | $6,856 | $88 |
| New patient visit (45+ min) | 32 | $5,084 | $159 |
| Diagnostic exam of bladder and urethra using an endoscope | 11 | $2,692 | $245 |
| Ultrasound measurement of bladder capacity after voiding | 73 | $1,181 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $521 | $35 |
| Urinalysis, manual test | 71 | $369 | $3 |
2019: 30 services
| Short return visit (20+ min) | 591 | $74,859 | $64 |
| Return visit (30+ min) | 321 | $42,333 | $92 |
| Diagnostic exam of bladder and urethra using an endoscope | 122 | $29,786 | $184 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $18,037 | None |
| New patient visit (45+ min) | 120 | $16,284 | $136 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 18 | $11,409 | $634 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 31 | $10,469 | $338 |
| Simple insertion of temporary bladder tube | 29 | $8,260 | $59 |
| Biopsy of prostate gland | 30 | $7,284 | $243 |
| Short return visit | 80 | $6,128 | $40 |
| Ultrasound measurement of bladder capacity after voiding | 303 | $6,009 | $13 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 15 | $5,478 | $342 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $4,922 | $259 |
| Ultrasound scan of pelvic region through rectum | 37 | $4,796 | $130 |
| Insertion of device into abdomen with pressure and urine flow rate study | 31 | $4,414 | $142 |
| Injection of drug or substance under skin or into muscle | 129 | $4,191 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,819 | $159 |
| Simple bladder irrigation and/or instillation | 31 | $2,686 | $73 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,978 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,697 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,585 | $93 |
| Urinalysis, manual test | 238 | $1,453 | $3 |
| Ultrasonic guidance for needle placement | 24 | $1,326 | $55 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 37 | $1,222 | $33 |
| Imaging of urinary tract following injection of a contrast agent | 24 | $613 | $24 |
| Emergency department visit with low level of medical decision making | 12 | $537 | $45 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $503 | $31 |
| Injection, garamycin, gentamicin, up to 80 mg | 181 | $419 | None |
| Electronic assessment of bladder emptying | 43 | $388 | $8 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $296 | $23 |
2018: 29 services
| Return visit (30+ min) | 442 | $69,006 | $91 |
| Short return visit (20+ min) | 514 | $63,008 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 115 | $24,504 | $158 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $21,548 | None |
| New patient visit (45+ min) | 124 | $16,236 | $131 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 18 | $11,251 | $625 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 26 | $10,661 | $368 |
| Ultrasound measurement of bladder capacity after voiding | 363 | $10,152 | $15 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 31 | $9,938 | $321 |
| Biopsy of prostate gland | 41 | $9,844 | $234 |
| Simple insertion of temporary bladder tube | 23 | $7,543 | $61 |
| Bcg (intravesical) per instillation | 11 | $7,323 | None |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 27 | $6,090 | $226 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $5,929 | $93 |
| Instillation of anti-cancer drug into bladder | 11 | $5,562 | $79 |
| Ultrasound scan of pelvic region through rectum | 47 | $4,648 | $95 |
| Insertion of device into abdomen with pressure and urine flow rate study | 30 | $3,412 | $114 |
| Short return visit | 51 | $3,273 | $41 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,883 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,880 | $180 |
| New patient visit (30+ min) | 29 | $2,719 | $94 |
| Simple bladder irrigation and/or instillation | 31 | $2,444 | $72 |
| Urinalysis, manual test | 281 | $1,790 | $3 |
| Injection of drug or substance under skin or into muscle | 42 | $1,518 | $20 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 37 | $1,340 | $34 |
| Electronic assessment of bladder emptying | 66 | $816 | $10 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $554 | $21 |
| Imaging of urinary tract following injection of a contrast agent | 30 | $528 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 175 | $375 | None |
2017: 24 services
| Short return visit (20+ min) | 596 | $84,379 | $59 |
| Return visit (30+ min) | 262 | $34,612 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 107 | $23,667 | $152 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $17,334 | None |
| Complete laser fragmentation of prostate including control of bleeding using an endoscope | 19 | $13,781 | $725 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 41 | $12,709 | $310 |
| Ultrasound measurement of bladder capacity after voiding | 325 | $11,443 | $18 |
| Biopsy of prostate gland | 45 | $10,566 | $235 |
| New patient visit (30+ min) | 113 | $9,539 | $84 |
| Simple insertion of temporary bladder tube | 24 | $6,986 | $59 |
| Ultrasound scan of pelvic region through rectum | 65 | $5,887 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,407 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,195 | $91 |
| Insertion of device into abdomen with pressure and urine flow rate study | 38 | $4,199 | $110 |
| New patient visit (45+ min) | 21 | $2,742 | $131 |
| Urinalysis, manual test | 296 | $1,958 | $3 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 49 | $1,614 | $33 |
| Simple bladder irrigation and/or instillation | 12 | $1,064 | $71 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,001 | $28 |
| Emergency department visit with low level of medical decision making | 15 | $728 | $49 |
| Electronic assessment of bladder emptying | 41 | $389 | $9 |
| Injection, garamycin, gentamicin, up to 80 mg | 186 | $383 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $314 | $17 |
| Imaging of urinary tract following injection of a contrast agent | 18 | $298 | $16 |
2016: 26 services
| Short return visit (20+ min) | 624 | $96,027 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 141 | $38,213 | $190 |
| Return visit (30+ min) | 239 | $32,288 | $90 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $22,985 | None |
| New patient visit (30+ min) | 144 | $12,341 | $86 |
| Ultrasound measurement of bladder capacity after voiding | 347 | $11,120 | $18 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 11 | $10,641 | $665 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 30 | $9,350 | $312 |
| Simple insertion of temporary bladder tube | 22 | $8,778 | $67 |
| Biopsy of prostate gland | 36 | $7,232 | $201 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $6,488 | $341 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $5,629 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,646 | $119 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $4,135 | $230 |
| Ultrasound scan of pelvic region through rectum | 40 | $3,717 | $88 |
| Insertion of device into abdomen with pressure and urine flow rate study | 29 | $3,151 | $109 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 32 | $3,025 | $95 |
| Emergency department visit with low level of medical decision making | 38 | $1,907 | $48 |
| Urinalysis, manual test | 300 | $1,894 | $3 |
| Ultrasonic guidance for needle placement | 31 | $1,804 | $58 |
| New patient visit (45+ min) | 15 | $1,665 | $111 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,196 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $486 | $18 |
| Imaging of urinary tract following injection of a contrast agent | 25 | $442 | $15 |
| Injection, garamycin, gentamicin, up to 80 mg | 180 | $325 | None |
| Electronic assessment of bladder emptying | 29 | $196 | $7 |
2015: 29 services
| Short return visit (20+ min) | 619 | $97,828 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 130 | $35,677 | $195 |
| Return visit (30+ min) | 211 | $31,948 | $98 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $21,223 | None |
| New patient visit (30+ min) | 126 | $12,472 | $99 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 35 | $11,080 | $317 |
| Simple insertion of temporary bladder tube | 32 | $9,951 | $69 |
| Ultrasound measurement of bladder capacity after voiding | 309 | $9,913 | $19 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 15 | $5,711 | $381 |
| Biopsy of prostate gland | 23 | $4,715 | $205 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $4,403 | $232 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 38 | $3,727 | $98 |
| Insertion of device into abdomen with pressure and urine flow rate study | 33 | $3,704 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,583 | $179 |
| Complete ultrasound scan behind abdominal cavity | 27 | $3,089 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,046 | $92 |
| Simple bladder irrigation and/or instillation | 27 | $2,526 | $77 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,452 | $94 |
| Injection of drug or substance under skin or into muscle | 66 | $2,094 | $25 |
| Emergency department visit with moderate level of medical decision making | 18 | $1,897 | $100 |
| New patient visit (45+ min) | 12 | $1,687 | $141 |
| Complete ultrasound scan of pelvis | 25 | $1,585 | $38 |
| Urinalysis, manual test | 237 | $1,367 | $3 |
| Ultrasonic guidance for needle placement | 23 | $1,336 | $58 |
| Electronic assessment of bladder emptying | 92 | $1,326 | $12 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,185 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $609 | $20 |
| Imaging of urinary tract following injection of a contrast agent | 24 | $512 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 186 | $341 | None |
2014: 30 services
| Short return visit (20+ min) | 570 | $73,597 | $62 |
| Return visit (30+ min) | 392 | $63,136 | $89 |
| Diagnostic exam of bladder and urethra using an endoscope | 127 | $30,371 | $189 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $22,778 | None |
| New patient visit (45+ min) | 109 | $14,838 | $136 |
| Ultrasound measurement of bladder capacity after voiding | 352 | $12,774 | $19 |
| Simple insertion of temporary bladder tube | 30 | $10,953 | $68 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 27 | $8,312 | $308 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $6,723 | $354 |
| Biopsy of prostate gland | 27 | $5,214 | $193 |
| New patient visit (30+ min) | 51 | $4,943 | $97 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 17 | $4,130 | $229 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,608 | $93 |
| Complete ultrasound scan behind abdominal cavity | 30 | $3,500 | $58 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 31 | $3,227 | $104 |
| Insertion of device into abdomen with pressure and urine flow rate study | 27 | $2,999 | $111 |
| Electronic assessment of bladder emptying | 158 | $2,933 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,680 | $122 |
| Ultrasound scan of pelvic region through rectum | 27 | $2,524 | $93 |
| Ultrasonic guidance for needle placement | 27 | $1,960 | $73 |
| Insertion of stent in ureter using an endoscope | 12 | $1,706 | $107 |
| Urinalysis, manual test | 285 | $1,700 | $3 |
| Emergency department visit with moderate level of medical decision making | 14 | $1,506 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,388 | $30 |
| Complete ultrasound scan of pelvis | 11 | $1,245 | $50 |
| Simple bladder irrigation and/or instillation | 13 | $1,116 | $80 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $908 | $20 |
| Injection of drug or substance under skin or into muscle | 23 | $841 | $24 |
| Imaging of urinary tract following injection of a contrast agent | 30 | $601 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 173 | $294 | None |
2013: 33 services
| Return visit (30+ min) | 441 | $75,947 | $90 |
| Short return visit (20+ min) | 450 | $52,473 | $62 |
| Diagnostic exam of bladder and urethra using an endoscope | 103 | $24,775 | $189 |
| New patient visit (45+ min) | 152 | $21,989 | $145 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $15,839 | None |
| Simple insertion of temporary bladder tube | 40 | $11,447 | $70 |
| Ultrasound measurement of bladder capacity after voiding | 290 | $9,059 | $19 |
| Complete laser fragmentation of prostate including control of bleeding using an endoscope | 13 | $8,808 | $678 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 26 | $7,984 | $307 |
| Crushing of stone of ureter using an endoscope | 20 | $7,006 | $350 |
| Ultrasonic guidance for needle placement | 32 | $6,918 | $216 |
| Biopsy of prostate gland | 32 | $6,568 | $205 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 24 | $5,721 | $229 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $5,393 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $5,131 | $119 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 35 | $3,798 | $106 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 15 | $3,745 | $121 |
| Complete ultrasound scan behind abdominal cavity | 28 | $3,660 | $64 |
| Insertion of device into abdomen with pressure and urine flow rate study | 32 | $3,567 | $111 |
| Ultrasound scan of pelvic region through rectum | 40 | $2,955 | $72 |
| Limited ultrasound scan of pelvis | 32 | $2,905 | $76 |
| Insertion of stent in ureter using an endoscope | 28 | $2,358 | $81 |
| New patient visit (30+ min) | 27 | $2,101 | $78 |
| Ultrasound scan of scrotum | 14 | $1,878 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 39 | $1,695 | $19 |
| Emergency department visit with moderate level of medical decision making | 18 | $1,599 | $89 |
| Electronic assessment of bladder emptying | 94 | $1,539 | $12 |
| Urinalysis, manual test | 239 | $1,394 | $3 |
| Simple bladder irrigation and/or instillation | 15 | $1,280 | $75 |
| Injection of drug or substance under skin or into muscle | 14 | $1,078 | $23 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $806 | $25 |
| Imaging of urinary tract following injection of a contrast agent | 30 | $481 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 155 | $233 | None |
Medicaid work
$44 in 2019
Medicaid paid $44 for 13 billed services this clinician did in 2019, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 13 | $44 |
| 2019 | 13 | 1 | 12 | $44 |
Drugs they prescribed that Part D paid
$23,790
Pharmacies billed $23,790 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
484 generic and 40 brand-name prescriptions · $23,790 in drug cost · 97 antibiotic prescriptions to 48 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 13 | $9,052 | $696 |
| Solifenacin | 74 | $2,413 | $33 |
| Tamsulosin | 150 | $1,712 | $11 |
| Finasteride | 72 | $1,122 | $16 |
| Estradiol | 16 | $1,062 | $66 |
See all 11 drugs
| Myrbetriq | 13 | $9,052 | $696 |
| Solifenacin | 74 | $2,413 | $33 |
| Tamsulosin | 150 | $1,712 | $11 |
| Finasteride | 72 | $1,122 | $16 |
| Estradiol | 16 | $1,062 | $66 |
| Nitrofurantoin Mono-Macro | 54 | $931 | $17 |
| Desmopressin Acetate | 24 | $647 | $27 |
| Oxybutynin Chloride Er | 17 | $363 | $21 |
| Nystatin | 11 | $130 | $12 |
| Sulfamethoxazole-Trimethoprim | 18 | $93 | $5 |
| Ciprofloxacin | 16 | $76 | $5 |
Year by year
| 2024 | 524 | 144 | None | 8% | $23,790 |
| 2023 | 466 | 123 | None | 11% | $38,112 |
| 2022 | 253 | 81 | None | 15% | $23,796 |
| 2021 | 109 | 47 | None | 21% | $9,910 |
| 2020 | 212 | 92 | None | 21% | $24,976 |
| 2019 | 1,473 | 300 | 3% (42) | None | $205,024 |
| 2018 | 1,416 | 305 | 4% (55) | None | $206,995 |
| 2017 | 1,482 | 299 | 5% (70) | None | $197,432 |
| 2016 | 1,483 | 306 | 4% (63) | None | $176,456 |
| 2015 | 1,398 | 298 | 5% (67) | 34% | $148,645 |
| 2014 | 1,307 | 298 | 5% (61) | None | $127,902 |
| 2013 | 1,241 | 325 | 4% (54) | None | $120,923 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Myrbetriq | 16 | $13,634 | $852 |
| Solifenacin | 61 | $4,180 | $69 |
| Estradiol | 18 | $1,930 | $107 |
| Tamsulosin | 130 | $1,818 | $14 |
| Finasteride | 65 | $1,104 | $17 |
| Nitrofurantoin Mono-Macro | 44 | $960 | $22 |
| Desmopressin Acetate | 19 | $702 | $37 |
| Oxybutynin Chloride Er | 39 | $604 | $15 |
| Sulfamethoxazole-Trimethoprim | 15 | $131 | $9 |
2022: 7 drugs
| Myrbetriq | 16 | $12,762 | $798 |
| Solifenacin | 36 | $1,796 | $50 |
| Desmopressin Acetate | 16 | $1,164 | $73 |
| Nitrofurantoin Mono-Macro | 32 | $635 | $20 |
| Tamsulosin | 51 | $530 | $10 |
| Oxybutynin Chloride Er | 16 | $325 | $20 |
| Finasteride | 23 | $213 | $9 |
2021: 2 drugs
| Solifenacin | 12 | $689 | $57 |
| Tamsulosin | 22 | $435 | $20 |
2020: 5 drugs
| Myrbetriq | 22 | $14,349 | $652 |
| Solifenacin | 15 | $1,425 | $95 |
| Tamsulosin | 83 | $858 | $10 |
| Oxybutynin Chloride Er | 18 | $744 | $41 |
| Finasteride | 12 | $275 | $23 |
2019: 25 drugs
| Myrbetriq | 192 | $105,244 | $548 |
| Vesicare | 39 | $18,192 | $466 |
| Toviaz | 33 | $13,912 | $422 |
| Potassium Citrate Er | 31 | $9,664 | $312 |
| Cialis | 24 | $8,453 | $352 |
| Solifenacin | 21 | $7,629 | $363 |
| Darifenacin Er | 19 | $5,396 | $284 |
| Tamsulosin | 396 | $5,246 | $13 |
| Oxybutynin Chloride Er | 109 | $4,259 | $39 |
| Rapaflo | 15 | $3,654 | $244 |
| Nitrofurantoin Mono-Macro | 92 | $2,489 | $27 |
| Silodosin | 20 | $2,486 | $124 |
| Desmopressin Acetate | 34 | $2,191 | $64 |
| Tolterodine Tartrate Er | 12 | $1,947 | $162 |
| Finasteride | 53 | $1,336 | $25 |
| Dutasteride | 21 | $670 | $32 |
| Nitrofurantoin | 14 | $613 | $44 |
| Ciprofloxacin | 71 | $408 | $6 |
| Allopurinol | 26 | $387 | $15 |
| Oxycodone-Acetaminophen | 42 | $372 | $9 |
| Indapamide | 22 | $311 | $14 |
| Amoxicillin-Clavulanate Potass | 18 | $174 | $10 |
| Sulfamethoxazole-Trimethoprim | 27 | $143 | $5 |
| Nystatin | 15 | $120 | $8 |
| Hydrochlorothiazide | 12 | $17 | $1 |
2018: 20 drugs
| Myrbetriq | 159 | $73,360 | $461 |
| Vesicare | 131 | $50,990 | $389 |
| Rapaflo | 68 | $19,297 | $284 |
| Cialis | 32 | $11,031 | $345 |
| Potassium Citrate Er | 33 | $9,592 | $291 |
| Darifenacin Er | 19 | $5,717 | $301 |
| Toviaz | 13 | $5,583 | $429 |
| Tamsulosin | 260 | $4,562 | $18 |
| Oxybutynin Chloride Er | 81 | $4,279 | $53 |
| Desmopressin Acetate | 42 | $2,910 | $69 |
| Nitrofurantoin Mono-Macro | 105 | $2,703 | $26 |
| Finasteride | 60 | $1,090 | $18 |
| Dutasteride | 24 | $872 | $36 |
| Ciprofloxacin | 115 | $584 | $5 |
| Oxycodone-Acetaminophen | 51 | $578 | $11 |
| Allopurinol | 14 | $426 | $30 |
| Cephalexin | 25 | $220 | $9 |
| Sulfamethoxazole-Trimethoprim | 24 | $93 | $4 |
| Nystatin | 11 | $82 | $7 |
| Hydrochlorothiazide | 13 | $17 | $1 |
2017: 23 drugs
| Vesicare | 175 | $68,202 | $390 |
| Myrbetriq | 104 | $41,137 | $396 |
| Rapaflo | 58 | $17,857 | $308 |
| Potassium Citrate Er | 41 | $11,625 | $284 |
| Cialis | 26 | $7,901 | $304 |
| Axiron | 11 | $6,432 | $585 |
| Darifenacin Er | 21 | $6,221 | $296 |
| Desmopressin Acetate | 62 | $4,225 | $68 |
| Oxybutynin Chloride Er | 73 | $4,027 | $55 |
| Tamsulosin | 222 | $3,648 | $16 |
| Nitrofurantoin Mono-Macro | 112 | $3,402 | $30 |
| Dutasteride-Tamsulosin | 26 | $2,965 | $114 |
| Dutasteride | 32 | $1,889 | $59 |
| Finasteride | 51 | $1,104 | $22 |
| Ciprofloxacin | 113 | $595 | $5 |
| Oxycodone-Acetaminophen | 63 | $426 | $7 |
| Nitrofurantoin | 13 | $331 | $25 |
| Oxybutynin Chloride | 14 | $282 | $20 |
| Sulfamethoxazole-Trimethoprim | 87 | $278 | $3 |
| Nystatin | 11 | $179 | $16 |
| Paroxetine | 11 | $61 | $6 |
| Amoxicillin | 15 | $50 | $3 |
| Cephalexin | 12 | $49 | $4 |
2016: 24 drugs
| Vesicare | 193 | $66,808 | $346 |
| Myrbetriq | 77 | $24,471 | $318 |
| Rapaflo | 49 | $12,631 | $258 |
| Potassium Citrate Er | 39 | $8,446 | $217 |
| Androgel | 11 | $7,160 | $651 |
| Cialis | 21 | $6,724 | $320 |
| Enablex | 19 | $6,617 | $348 |
| Tamsulosin | 245 | $5,165 | $21 |
| Nitrofurantoin Mono-Macro | 102 | $4,825 | $47 |
| Oxybutynin Chloride Er | 67 | $4,561 | $68 |
| Toviaz | 14 | $3,962 | $283 |
| Desmopressin Acetate | 62 | $3,392 | $55 |
| Jalyn | 15 | $2,504 | $167 |
| Dutasteride-Tamsulosin | 13 | $2,409 | $185 |
| Finasteride | 73 | $1,109 | $15 |
| Dutasteride | 13 | $1,078 | $83 |
| Ciprofloxacin | 158 | $994 | $6 |
| Oxycodone-Acetaminophen | 57 | $618 | $11 |
| Oxybutynin Chloride | 24 | $511 | $21 |
| Nitrofurantoin | 14 | $497 | $35 |
| Bicalutamide | 11 | $319 | $29 |
| Allopurinol | 20 | $256 | $13 |
| Sulfamethoxazole-Trimethoprim | 53 | $251 | $5 |
| Cephalexin | 16 | $164 | $10 |
2015: 24 drugs
| Vesicare | 180 | $52,378 | $291 |
| Myrbetriq | 53 | $16,628 | $314 |
| Enablex | 43 | $12,608 | $293 |
| Rapaflo | 46 | $8,836 | $192 |
| Potassium Citrate Er | 21 | $6,488 | $309 |
| Tamsulosin | 202 | $5,873 | $29 |
| Oxybutynin Chloride Er | 93 | $5,389 | $58 |
| Desmopressin Acetate | 38 | $3,913 | $103 |
| Avodart | 19 | $3,808 | $200 |
| Jalyn | 20 | $3,575 | $179 |
| Cialis | 12 | $3,065 | $255 |
| Nitrofurantoin Mono-Macro | 69 | $3,039 | $44 |
| Toviaz | 12 | $2,670 | $222 |
| Ciprofloxacin | 164 | $840 | $5 |
| Finasteride | 68 | $782 | $11 |
| Oxycodone-Acetaminophen | 53 | $550 | $10 |
| Venlafaxine | 11 | $471 | $43 |
| Oxybutynin Chloride | 20 | $431 | $22 |
| Bicalutamide | 12 | $406 | $34 |
| Nitrofurantoin | 11 | $377 | $34 |
| Allopurinol | 22 | $298 | $14 |
| Sulfamethoxazole-Trimethoprim | 64 | $270 | $4 |
| Cephalexin | 14 | $116 | $8 |
| Hydroxyzine | 11 | $76 | $7 |
2014: 20 drugs
| Vesicare | 126 | $32,338 | $257 |
| Myrbetriq | 60 | $15,563 | $259 |
| Enablex | 46 | $10,541 | $229 |
| Avodart | 49 | $8,463 | $173 |
| Urocit-K | 26 | $7,656 | $294 |
| Rapaflo | 47 | $7,569 | $161 |
| Testim | 16 | $6,436 | $402 |
| Androgel | 14 | $6,146 | $439 |
| Desmopressin Acetate | 51 | $6,010 | $118 |
| Oxybutynin Chloride Er | 65 | $4,650 | $72 |
| Tamsulosin | 199 | $3,453 | $17 |
| Nitrofurantoin Mono-Macro | 75 | $3,094 | $41 |
| Jalyn | 12 | $1,742 | $145 |
| Ciprofloxacin | 163 | $797 | $5 |
| Finasteride | 63 | $795 | $13 |
| Hydrocodone-Acetaminophen | 22 | $563 | $26 |
| Sulfamethoxazole-Trimethoprim | 51 | $290 | $6 |
| Oxycodone-Acetaminophen | 27 | $201 | $7 |
| Cephalexin | 19 | $169 | $9 |
| Allopurinol | 12 | $114 | $9 |
2013: 20 drugs
| Vesicare | 101 | $24,450 | $242 |
| Androgel | 30 | $12,327 | $411 |
| Myrbetriq | 46 | $11,258 | $245 |
| Enablex | 54 | $10,860 | $201 |
| Avodart | 50 | $8,383 | $168 |
| Desmopressin Acetate | 57 | $7,571 | $133 |
| Toviaz | 27 | $6,229 | $231 |
| Rapaflo | 34 | $5,323 | $157 |
| Nitrofurantoin Mono-Macro | 95 | $5,188 | $55 |
| Urocit-K | 23 | $4,784 | $208 |
| Oxybutynin Chloride Er | 50 | $4,203 | $84 |
| Tamsulosin | 172 | $3,008 | $17 |
| Jalyn | 15 | $1,979 | $132 |
| Finasteride | 58 | $1,130 | $19 |
| Ciprofloxacin | 152 | $784 | $5 |
| Sulfamethoxazole-Trimethoprim | 53 | $288 | $5 |
| Levofloxacin | 13 | $196 | $15 |
| Cephalexin | 21 | $154 | $7 |
| Oxycodone-Acetaminophen | 26 | $153 | $6 |
| Hydrocodone-Acetaminophen | 17 | $112 | $7 |
Money from drug and device companies
$191 in 2025
| 2025 | 1 | 3 | None | $191 |
| 2024 | 2 | 2 | None | $133 |
| 2023 | 1 | 1 | None | $16 |
| 2021 | 1 | 1 | $600 | $600 |
| 2020 | 1 | 1 | $450 | $450 |
| 2019 | 14 | 42 | $600 | $1,279 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Procept Biorobotics | Aquabeam Robotic System | $191 | 3 payments
|
See all 3 published payments
| Procept Biorobotics | Meals · 2025-05-03 | Aquabeam Robotic System | $19 |
| Procept Biorobotics | Meals · 2025-05-03 | Aquabeam Robotic System | $26 |
| Procept Biorobotics | Meals · 2025-05-02 | Aquabeam Robotic System | $146 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $133
| Intuitive Surgical | Da Vinci Surgical System | $98 | 1 payment
|
| Ethicon US | Ethicon | $35 | 1 payment
|
2023: $16
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $16 | 1 payment
|
2021: $600
| Intuitive Surgical | Da Vinci Surgical System | $600 | 1 payment
|
2020: $450
| Intuitive Surgical | Da Vinci Surgical System | $450 | 1 payment
|
2019: $1,279
| Intuitive Surgical | Da Vinci Surgical System | $600 | 1 payment
|
| Pfizer | Xtandi | $146 | 9 payments
|
| Janssen Biotech | Erleada | $127 | 11 payments
|
| Ferring Pharmaceuticals | Nocdurna | $94 | 5 payments
|
| Coloplast | Speedicath | $60 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $44 | 2 payments
|
| Allergan | Botox | $38 | 2 payments
|
| Boston Scientific | General Bph | $36 | 2 payments
|
| AbbVie | Lupron Depot | $33 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $29 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $23 | 1 payment
|
| Dentsply Ih | Lofric | $20 | 1 payment
|
| Merck Sharp & Dohme | Zerbaxa | $16 | 1 payment
|
| Photocure | Cysview | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1841277944
- Licence
- CA A96007, NC 9601253California A96007: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2005-12-29
- NPI last updated
- 2024-08-05
- NPI record certified
- 2024-08-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2900 Whipple Ave Ste 132, Redwood City, CA, 94062